The Patent Finder

Terms ending in 2030

ZymoGenetics Inc.

Every in-force patent on ZymoGenetics Inc.'s record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 10,005,837B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
In force
 · Medium confidence
Zymogenetics, Inc.In forceMedium confidence
US 8,071,090Stabilized Thrombin Compositions
In force
 · High confidence
Baxter International, Inc.In forceHigh confidence
US 10,570,187Soluble Hybrid Fcgamma Receptors and Related Methods
In force
 · High confidence
ZymoGenetics, Inc.In forceHigh confidence
US 8,470,979Humanized Antibody Molecules Specific for IL-31
In force
 · High confidence
ZymoGenetics, Inc.In forceHigh confidence
US 9,663,566Soluble Hybrid Fcgamma Receptors and Related Methods
In force
 · High confidence
ZymoGenetics, Inc.In forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by ZymoGenetics Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited